Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234245 | 0.66 | L3MBTL1 (0.39) | — | |
| SCHEMBL7795415 | 0.63 | P2RX3 (0.31) | — | |
| SCHEMBL6233396 | 0.63 | KDM4E (0.36) | — | |
| SCHEMBL5956305 | 0.62 | — | — | |
| SCHEMBL5956026 | 0.62 | — | — | |
| SCHEMBL6378031 | 0.62 | PKM (0.42) | — | |
| SCHEMBL2383860 | 0.61 | — | — | |
| SCHEMBL6233301 | 0.60 | GAA (0.46) | — | |
| SCHEMBL11024134 | 0.60 | GAA (0.46) | — | |
| SCHEMBL14379071 | 0.59 | TSHR (0.31) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0160618-A1 | Hydantoin derivatives and pharmaceutical compositions containing them | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1985-11-06 | — | — | EP | claimed |
| EP-3639821-B1 | CARCINOGENESIS INHIBITOR | NAT CANCER CT (JP) | 2024-08-28 | — | — | EP | disclosed |
| CN-110740729-B | Carcinogenesis inhibitor | 国立研究开发法人国立癌症研究中心 | 2023-05-16 | — | — | CN | disclosed |
| US-11464762-B2 | Carcinogenesis inhibitor | NATIONAL CANCER CENTER (JP) | 2022-10-11 | — | — | US | disclosed |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | NATIONAL CANCER CENTER (JP) | 2020-09-03 | — | — | US | disclosed |
| EP-3639821-A1 | CARCINOGENESIS INHIBITOR | National Cancer Center (JP) | 2020-04-22 | — | — | EP | disclosed |
| EP-1243261-B1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2005-04-27 | — | — | EP | disclosed |
| EP-1018339-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of intractable vasculitis. | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2003-05-02 | — | — | EP | disclosed |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-10-10 | — | — | US | disclosed |
| EP-1243261-A1 | Use of a hydantoin derivative in a pharmaceutical composition against hypoalbuminaemia | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-25 | — | — | EP | disclosed |
| US-6451831-B1 | TREATMENT WITH HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2002-09-17 | — | — | US | disclosed |
| US-6251929-B1 | ADMINISTERING TO A PATIENT A HYDANTOIN DERIVATIVES AND SALTS AS THERAPEUTIC AND PREVENTIVE AGENTS FOR INTRACTABLE VASCULITIS SUCH AS MALIGNANT RHEUMATOID ARTHRITIS(MRA), PERIARTERITIS NODOSA, WEGENER'S GRANULOMATOSIS ETC. | NIPPON ZOKI PHARMACEUTICALS CO., LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0780125-B1 | Use of hydantoin derivatives for the preparation of a medicament for the treatment of dieases associated with the presence of active oxygen and free radicals | NIPPON ZOKI PHARMACEUTICAL CO (JP) | 2001-04-18 | — | — | EP | disclosed |
| US-6197806-B1 | USING A HYDANTOIN DERIVATIVE | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-1018339-A1 | Therapeutic agent for intractable vasculitis | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 2000-07-12 | — | — | EP | disclosed |
| EP-0780125-A2 | Pharmaceutical composition containing a hydantoin derivative and use of said derivative | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| EP-0160618-B1 | HYDANTOIN DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) | 1991-08-14 | — | — | EP | disclosed |
| US-4647574-A | Hypoglycemic hydantoin derivatives | NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) | 1987-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11464762-B2 | Carcinogenesis inhibitor | APC, MKI67, HRAS | TSHR 4604/4885 |
| US-20020147228-A1 | AGENT FOR HYPOALBUMINAEMIA | ALB, TTR, SERPINA6 | TSHR 3443/4885 |
| US-20200276163-A1 | CARCINOGENESIS INHIBITOR | APC, MKI67, HRAS | TSHR 4604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.